Vetter’s decades of experience as a contract manufacturer providing fill & finish for injectable drugs helps deliver results for both large and small companies.
Vetter can help you identify and develop the right packaging strategies for your compound, from clinical dev to commercialization to life cycle management.
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.
At Emergent BioSolutions, our mission is to protect and enhance life. In working together, we envision protecting or enhancing 1 billion lives by 2030.
The AJILITY platform streamlines your drug product manufacturing program, helping you get lifesaving therapeutics to patients in less time with less complexity.
Don’t miss this upcoming auction featuring assets from a natural products and nutritional chemistry facility. The auction will take place February 12-18, 2021.